Trial Profile
Sargramostim Safety and Tolerability With Standard Of Care Ipilimumab Containing Therapy in Patients With Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Sargramostim (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SALIENT
- Sponsors Partner Therapeutics
- 13 Sep 2023 Status changed from suspended to withdrawn prior to enrolment.
- 30 Nov 2022 Planned End Date changed from 1 Dec 2025 to 1 Sep 2025.
- 30 Nov 2022 Planned primary completion date changed from 1 Dec 2025 to 1 Sep 2025.